Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study comparing T-DM1 with pertuzumab, trastuzumab and docetaxel in elderly patients with advanced stage HER2 positive breast cancer (JCOG1607, HERB TEA study)

Next Previous
X
Search
Trial Profile

A phase III study comparing T-DM1 with pertuzumab, trastuzumab and docetaxel in elderly patients with advanced stage HER2 positive breast cancer (JCOG1607, HERB TEA study)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Docetaxel
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms HERB TEA study

    • Most Recent Events

    • 02 Jul 2024 Status changed from recruiting to discontinued.
    • 04 Jun 2024 Results of subgroup analysis investigating the subgroup that could benefit from T-DM1 with fewer side effects as a first-line treatment presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Feb 2024 Planned number of patients changed from 330 to 250.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top